Genentech Reports Phase III Divarasib Efficacy Results in Lung Cancer
Genentech said its Phase III KRASCENDO 1 study found investigational divarasib more efficacious than current standard of care in previously treated KRAS G12C-mutated lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.